Focus:
News
-
20 August 2019
Vaxxilon receives grant to develop new prophylactic vaccine
Switzerland-based synthetic vaccines firm Vaxxilon has received a funding grant from CARB-X to support the development of a prophylactic, multivalent vaccine against carbapenem-resistant Klebsiella pneumoniae (crKP).
-
20 August 2019
Mateon and PointR to merge into AI-driven oncology firm
Immuno-oncology company Mateon Therapeutics has signed a definitive agreement to merge with PointR Data, a computer and artificial intelligence (AI) company, to form an AI-driven firm focused on cancer treatment.
-
20 August 2019
Nabriva’s bacterial pneumonia drug gets US regulatory approval
Nabriva Therapeutics has received US regulatory approval for Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia (CABP).
-
19 August 2019
Researchers develop compound to reduce injury due to heart attacks
Researchers from Virginia Tech University (VT) have developed a variant of the compound alphaCT1, which can improve heart attack recovery if administered during, or soon after, a heart attack.
-
19 August 2019
Celgene’s bone marrow cancer drug Inrebic secures FDA approval
Celgene has received the US Food and Drug Administration (FDA) approval for the use of its Inrebic (fedratinib) drug to treat adults with myelofibrosis, a rare bone marrow cancer.
-
19 August 2019
Juvenescence closes $100m series B round for longevity therapies
UK-based life sciences firm Juvenescence has announced a $100m series B financing round to support the development of artificial intelligence (AI)-based therapeutics and technologies for ageing diseases.
-
16 August 2019
FDA approves first non-controlled substance narcolepsy drug
Harmony Biosciences has announced the US Food and Drug Administration (FDA) has approved Wakix (pitolisant) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy.
-
16 August 2019
Genentech gets FDA approval for tumour-agnostic drug Rozlytrek
The US Food and Drug Administration (FDA) has approved Roche division Genentech’s tumour-agnostic drug Rozlytrek, which targets a specific genetic defect called neurotrophic tyrosine receptor kinase (NTRK).
-
16 August 2019
UK to set up freight service for medicines supply post Brexit
The UK Department of Health and Social Care has announced a £25m contract for express freight service to deliver medicines and medical products after the country exits the European Union...
-
15 August 2019
AstraZeneca and Merck’s Lynparza continues to perform well in ovarian cancer
AstraZeneca and Merck have announced that Lynparza (olaparib), the primary product in their ongoing oncology collaboration, has performed better than the standard of care as a first line maintenance treatment...